Poncirin attenuates CCL4-induced liver injury through inhibition of oxidative stress and inflammatory cytokines in mice.
Anti-oxidant enzymes
CCL4
Cytokines
Oxidative stress
Poncirin
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
19 Apr 2020
19 Apr 2020
Historique:
received:
16
12
2019
accepted:
26
03
2020
entrez:
21
4
2020
pubmed:
21
4
2020
medline:
2
10
2020
Statut:
epublish
Résumé
In the present study, the poncirin which is flavonoid-7-o-glycosides (isolated from the Poncirus trifoliata) in nature was evaluated against the Carbon tetra chloride (CCL4)-induced liver injury. The poncirin have been reported for various anti-inflammatory, analgesic activity etc. Based on the previous studies it was anticipated that the poncirin will ameliorate CCL4-induced liver injury. The CCL4-induced acute and chronic liver injury model (albino BALB/c mice) was used. Following the induction of the liver injury various parameters such as food and water intake, body weight and weight to dry ratio changes were assessed. Furthermore, various hematological, biochemical parameters and histological studies such as hemotoxylin and eosin (H and E) staining were performed. The poncirin treatment was also evaluated against the pro-inflammatory cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) using enzyme link immunosorbant assay (ELISA). The Swiss Target prediction software was used to investigate interaction of the poncirin on the various hepatic enzymes. The poncirin treatment markedly improved the behavioral parameters such as food and water intake. The liver weight variation was attenuated and total body was improved markedly. The hematological and biochemical parameters were significantly improved compared to the CCL4 treated groups. The anti-oxidants were induced, while oxidative stress markers were reduced promisingly. The H and E staining showed that poncirin treatment significantly improved the histology of liver compared to the CCL4 treated group. Furthermore, the poncirin treatment also evidently decreased the inflammatory mediators. The poncirin treatment showed marked improvement in behavioral, biochemical and histological parameters following CCL4-induced liver injury. Additionally, the poncirin treatment also markedly improved the antioxidant enzymes, attenuated the oxidative stress markers and inflammatory cytokines.
Sections du résumé
BACKGROUND
BACKGROUND
In the present study, the poncirin which is flavonoid-7-o-glycosides (isolated from the Poncirus trifoliata) in nature was evaluated against the Carbon tetra chloride (CCL4)-induced liver injury. The poncirin have been reported for various anti-inflammatory, analgesic activity etc. Based on the previous studies it was anticipated that the poncirin will ameliorate CCL4-induced liver injury.
METHODS
METHODS
The CCL4-induced acute and chronic liver injury model (albino BALB/c mice) was used. Following the induction of the liver injury various parameters such as food and water intake, body weight and weight to dry ratio changes were assessed. Furthermore, various hematological, biochemical parameters and histological studies such as hemotoxylin and eosin (H and E) staining were performed. The poncirin treatment was also evaluated against the pro-inflammatory cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) using enzyme link immunosorbant assay (ELISA). The Swiss Target prediction software was used to investigate interaction of the poncirin on the various hepatic enzymes.
RESULTS
RESULTS
The poncirin treatment markedly improved the behavioral parameters such as food and water intake. The liver weight variation was attenuated and total body was improved markedly. The hematological and biochemical parameters were significantly improved compared to the CCL4 treated groups. The anti-oxidants were induced, while oxidative stress markers were reduced promisingly. The H and E staining showed that poncirin treatment significantly improved the histology of liver compared to the CCL4 treated group. Furthermore, the poncirin treatment also evidently decreased the inflammatory mediators.
CONCLUSIONS
CONCLUSIONS
The poncirin treatment showed marked improvement in behavioral, biochemical and histological parameters following CCL4-induced liver injury. Additionally, the poncirin treatment also markedly improved the antioxidant enzymes, attenuated the oxidative stress markers and inflammatory cytokines.
Identifiants
pubmed: 32307011
doi: 10.1186/s12906-020-02906-7
pii: 10.1186/s12906-020-02906-7
pmc: PMC7168870
doi:
Substances chimiques
Cytokines
0
Flavonoids
0
poncirin
8MUY4P95B4
Carbon Tetrachloride
CL2T97X0V0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115Références
Phytother Res. 2019 Feb;33(2):327-341
pubmed: 30456885
Proc Natl Acad Sci U S A. 2009 Sep 8;106(36):15424-9
pubmed: 19706381
J Hepatol. 2007 Jun;46(6):1040-6
pubmed: 17335931
Life Sci. 2019 Dec 15;239:116888
pubmed: 31639401
BMC Pharmacol Toxicol. 2019 Sep 11;20(1):57
pubmed: 31511086
Front Pharmacol. 2018 Mar 20;9:140
pubmed: 29615898
Food Chem Toxicol. 2004 Mar;42(3):429-38
pubmed: 14871584
Bioorg Med Chem. 2005 Jun 1;13(11):3811-20
pubmed: 15863007
Int Immunopharmacol. 2018 Aug;61:306-316
pubmed: 29909234
Biochem Pharmacol. 2002 Dec 1;64(11):1579-89
pubmed: 12429347
Int Immunopharmacol. 2020 Mar;80:106209
pubmed: 32004924
Cell. 2003 Jan 24;112(2):181-92
pubmed: 12553907
Toxicology. 2013 Nov 16;313(2-3):73-82
pubmed: 23238274
Ann Intern Med. 2000 Feb 15;132(4):296-305
pubmed: 10681285
J Ethnopharmacol. 2011 Jun 22;136(2):309-15
pubmed: 21549823
Hepatology. 2002 Sep;36(3):562-72
pubmed: 12198648
J Leukoc Biol. 2005 May;77(5):598-625
pubmed: 15689384
Pharm Res. 2013 Sep;30(9):2174-87
pubmed: 23462933
J Nucl Med. 2003 Feb;44(2):213-21
pubmed: 12571212
Biochem J. 2011 Feb 1;433(3):505-14
pubmed: 21044047
Int Immunopharmacol. 2019 Aug;73:451-460
pubmed: 31154290
Toxicol Rep. 2015 Jun 11;2:891-895
pubmed: 28962426
Gut. 2004 Mar;53(3):413-9
pubmed: 14960526
J Cell Biochem. 2011 Aug;112(8):2179-88
pubmed: 21480361
Drug Metab Rev. 2011 Feb;43(1):41-52
pubmed: 21108564
Biochemistry. 2010 Feb 9;49(5):835-42
pubmed: 20050630
Phytother Res. 2005 Sep;19(9):744-9
pubmed: 16220565
Arch Pharm Res. 2004 Jan;27(1):106-10
pubmed: 14969348
Singapore Med J. 2002 Feb;43(2):077-85
pubmed: 11993894
Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):135-42
pubmed: 15539622
Biol Pharm Bull. 2010;33(6):983-7
pubmed: 20522963
J Ethnopharmacol. 2013 Jan 30;145(2):626-37
pubmed: 23237934
Clin Exp Pharmacol Physiol. 2000 May-Jun;27(5-6):358-63
pubmed: 10831236
Nucleic Acids Res. 2019 Jul 2;47(W1):W357-W364
pubmed: 31106366
Hum Mol Genet. 2002 Mar 1;11(5):525-34
pubmed: 11875047
BMC Complement Altern Med. 2016 Nov 4;16(1):438
pubmed: 27814700
J Ethnopharmacol. 2007 Nov 1;114(2):169-73
pubmed: 17870264
J Dairy Sci. 2008 Sep;91(9):3300-10
pubmed: 18765589
Hepatology. 2003 Feb;37(2):343-50
pubmed: 12540784
J Anal Methods Chem. 2014;2014:296838
pubmed: 25180132
Eur J Pharmacol. 2019 Jan 15;843:292-306
pubmed: 30529194
Nat Med. 2013 Apr;19(4):500-5
pubmed: 23455711
Nat Genet. 2004 Sep;36(9):969-77
pubmed: 15322543
Food Chem Toxicol. 2006 Dec;44(12):1989-96
pubmed: 16914248
Toxicol Appl Pharmacol. 2004 Sep 15;199(3):193-209
pubmed: 15364537
J Biol Chem. 2002 Jan 18;277(3):1705-11
pubmed: 11694526
Am J Pathol. 2001 Dec;159(6):2081-8
pubmed: 11733358